Clinical Trials Browser

fluzoparib × Breast × Clear all

NCT05656131 2026-03-17

Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer

Phase 2 Suspended

Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer

NCT07353437 2026-01-20

Fluzoparib as Adjuvant Treatment in Patients With Germline Homologous Recombination Repair (HRR) Mutated Primary Breast Cancer (Flamenco)

Phase 2 Not yet recruiting

Breast Neoplasms

NCT06255392 2025-08-15

Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer

Phase 3 Recruiting

Fludzoparib" and Anti-angiogenic

NCT05594095 2024-10-04

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT06561022 2024-08-19

abemaSNF1/3

Phase 2 Not yet recruiting

Breast Neoplasms

NCT06254066 2024-02-12

Adebrelimab Combined With Fluzoparib in HRD-positive HR +/HER2- Advanced Breast Cancer

Phase 2 Not yet recruiting

Female Breast Cancer Patients

NCT05891093 2024-02-08

Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)

Phase 3 Recruiting

Breast Neoplasms

NCT05759546 2024-02-06

PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer

Phase 2 Recruiting

Breast Cancer Metastatic

NCT05928780 2023-07-03

An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC in First-line Treatment (FUTURE-Trop2)

Phase 1/2 Unknown

Triple Negative Breast Neoplasms

NCT05761470 2023-03-09

IMPARP

Phase 2 Recruiting

Her-2 Negative Breast Cancer

NCT03945604 2022-08-12

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC

Phase 1 Completed

Triple Negative Breast Neoplasms

NCT03805399 2022-08-10

FUTURE

Phase 1/2 Unknown

Triple Negative Breast Neoplasms

NCT04355858 2022-07-26

MULAN

Phase 2 Unknown

Breast Neoplasms, Neoplasm Metastasis

NCT03075462 2022-07-01

A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients

Phase 1 Completed

BreastGynecologic

Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT04296370 2020-08-10

A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation

Phase 3 Unknown

Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation